Devices & Diagnostics

Startup developing MRI-compatible tools raises more than $4M from angels

A Burnsville, Minnesota startup developing MRI- compatible electrophysiology tools has raised $4.1 million, according to a regulatory filing. The filing was an amendment to a September filing. Imricor Medical Systems CEO Steven Wedan said that the company is raising another $200,000. The money will be used in product development and in getting regulatory clearance. Imricor […]

A Burnsville, Minnesota startup developing MRI- compatible electrophysiology tools has raised $4.1 million, according to a regulatory filing. The filing was an amendment to a September filing.

Imricor Medical Systems CEO Steven Wedan said that the company is raising another $200,000. The money will be used in product development and in getting regulatory clearance.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Imricor is developing the Vision MR EP (electrophysiology) Ablation Catheter to be used to provide cardiac ablation in the MR lab. Through cardiac ablation treatment, a catheter is used to deliver energy to a portion of the heart muscle that is causing arrhythmia or irregular heart rhythm.

Another product the company is developing is the Horizon EP Recording System. It can perform the standard recording and pacing function of regular recording and pacing systems, but is equipped with a patented technology that makes it compatible for use in an MR environment.

Wedan said the products are being tested, but he declined to say when they will be submitted to the U.S. Food and Drug Administration for approval.

Including this current round, Imricor has raised $10 million with a mixture of equity and grants. Only angels have invested in the company so far, Wedan said. Imricor has 10 full-time employees.